Development of Retinitis pigmentosa treatment

retinis

Ophthalmic project for Retinitis pigmentosa treatment

 

Retinitis Pigmentosa (RP) is an inherited eye disease that causes severe vision impairment and, currently, there is no cure for it. It affects  1 in 3,500 to 1 in 4,000 people in the United States and Europe (which is roughly 260 - 300 thousand patients) and is recognised as orphan disease by EMA and FDA

Profarma develops ProMER GF, which is designed and modified according to the Company’s ProMERTM technology, that is then incorporated into innovative monodisperse microfluidic particles for sustained release delivery

As a result of the injections of ProMER GF and their anti-apoptotic, anti-inflammatory and neuroprotective effects, retinal photoreceptors degeneration are protected from the death.

Company has completed technological development and finished preclinical studies

Profarma develops ProMER GF, which is designed and modified according to the Company’s ProMERTM technology, that is then incorporated into innovative monodisperse microfluidic particles for sustained release delivery
Contacts
JSC "PROFARMA"


V.A. Graiciuno 6, LT-02241,
Vilnius, Lithuania


Tel. +370 5 2629761,
E-mail: info@profarma.lt